key: cord-0319985-ner59i85
authors: Lee, Katherine S.; Wong, Ting Y.; Russ, Brynnan P.; Horspool, Alexander M.; Miller, Olivia A.; Rader, Nathaniel A.; Givi, Jerome P.; Winters, Michael T.; Wong, Zeriel YA.; Cyphert, Holly A.; Denvir, James; Stoilov, Peter; Barbier, Mariette; Roan, Nadia R.; Amin, Md. Shahrier; Martinez, Ivan; Bevere, Justin R.; Damron, F. Heath
title: SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice
date: 2022-01-19
journal: bioRxiv
DOI: 10.1101/2022.01.18.476863
sha: 700fc2809190c36601c940d3b34c81fd09523219
doc_id: 319985
cord_uid: ner59i85

The COVID-19 pandemic has been fueled by novel variants of concern (VOC) that have increased transmissibility, receptor binding affinity, and other properties that enhance disease. The goal of this study is to characterize unique pathogenesis of the Delta VOC strain in the K18-hACE2-mouse challenge model. Challenge studies suggested that the lethal dose of Delta was higher than Alpha or Beta strains. To characterize the differences in the Delta strain’s pathogenesis, a time-course experiment was performed to evaluate the overall host response to Alpha or Delta variant challenge. qRT-PCR analysis of Alpha- or Delta- challenged mice revealed no significant difference between viral RNA burden in the lung, nasal wash or brain. However, histopathological analysis revealed high lung tissue inflammation and cell infiltration following Delta- but not Alpha-challenge at day 6. Additionally, pro-inflammatory cytokines were highest at day 6 in Delta-challenged mice suggesting enhanced pneumonia. Total RNA-sequencing analysis of lungs comparing infected to uninfected mice revealed that Alpha-challenged mice have more total genes differentially activated, conversely, Delta-challenged mice have a higher magnitude of differential gene expression. Delta-challenged mice have increased interferon-dependent gene expression and IFN-γ production compared to Alpha. Analysis of TCR clonotypes suggested that Delta challenged mice have increased T-cell infiltration compared to Alpha challenged. Our data suggest that Delta has evolved to engage interferon responses in a manner that may enhance pathogenesis. The in vivo and in silico observations of this study underscore the need to conduct experiments with VOC strains to best model COVID-19 when evaluating therapeutics and vaccines. Importance The Delta variant of SARS-CoV-2 is known to be more transmissible and cause severe disease in human hosts due to mutations in its genome that are divergent from previous variants of concern (VOC). Our study evaluates the pathogenesis of Delta in the K18-hACE2 mouse model compared to the Alpha VOC. We observed that relative to Alpha, Delta challenge results in enhanced inflammation and tissue damage with stronger antiviral responses. These observations provide insight into Delta’s unique pathogenesis.

The COVID-19 pandemic is being perpetuated by the emergence of "Variants of Concern" 61 (VOC), mutant strains of SARS-COV-2 with enhanced disease-causing abilities. Early in the 62 pandemic, strains obtained the D614G mutation that enhanced binding of the spike protein to 63 the host hACE2 receptor. The mutation quickly became dominant in the circulating strains 64 around the world. Several potential variant strains were noted and monitored but few However, the efficacy of the BNT162b2 vaccine was slightly diminished in the context of the 78 Alpha (93.7% efficacy) (20).

As Alpha, Beta, and Gamma continued to spread, the Delta variant (B.1.617.2) was identified in 80 India, resulting in a massive surge of COVID-19 cases in the country (21). Unsurprisingly, Delta 81 was able to cause breakthrough cases of infection within a portion of fully vaccinated people, 82 decreasing the overall efficacy of ChAdOx1, mRNA-1273, or BNT162b2 vaccines (20,22-24) . In spike, which contributes to the increased fitness and transmissibility of many VOC strains 92 (28, 29) . Some strains of Delta are reported to harbor the K417N mutation previously found in 93 Beta and Gamma, which sparked debate over designating the strain as a new variant (30, 31) .

This mutant strain was labeled as "Delta Plus." Additional mutations within the spike protein of 95 Delta include P681R, which diverge from other VOC and help to enhance ACE2 receptor 96 binding and cellular entry, contributing to reported increases in Delta's pathogenicity (32).

To characterize the pathogenicity of Delta (utilizing strain B.1.617.2) and how it diverges from 98 prior VOC (WA-1, Alpha, and Beta strains), we performed a time-course challenge study in K18-99 hACE2 transgenic mice, which were intranasally challenged with Alpha and Delta strains.

Through analysis of viral load, tissue pathology, cytokine profiling, and total transcriptomics of 101 the lung, we discovered that Delta causes increased interferon type I and II responses corresponding with greater lung inflammation when compared to Alpha. These data help to 103 advance pre-clinical models of COVID-19 as well as serve as a benchmark to compare past and 104 future VOC strains.

The Delta Variant of SARS-CoV-2 has a greater LD100 than Alpha and Beta VOCs in K18-108 hACE2 mice. To date, most K18-hACE2 mouse or Golden Syrian hamster studies have 109 utilized ancestral viral strains of SARS-CoV-2 (e.g., WA-1, D614G, B.1 Wuhan), and few studies 110 have been performed with emergent VOC (2, 17, 18, (33) (34) (35) (36) (37) (38) (39) . Early studies in K18-hACE-mice 111 with a variety of viral strains used a wide range of challenge doses from as low as 100 PFU to 112 as high as 10 5 PFU (40) (41) (42) . In pilot studies with the Alpha and Beta variants, we evaluated 10 5 113 PFU (high dose) and observed mortality as early as day 4 post challenge, suggesting that VOCs 114 have enhanced virulence in K18-hACE-mice compared to WA-1 ancestral strain (data not 115 shown). We then aimed to identify an appropriate challenge dose for WA-1, Alpha, Beta, and

Delta VOC that could cause symptomatic disease for appropriate comparisons between the 117 subtle aspects of variant pathogenicity masked by lethal challenge doses. At the low dose of 10 3 118 PFU, WA-1 challenge only resulted in morbidity of 50% of the mice (Fig. 1A) . We observed that 119 a challenge dose of 10 3 PFU using Alpha or Beta resulted in 80% and 100% mortality, 120 respectively by day 7 post challenge. Although this comparison between Alpha and Beta 121 challenge at 10 3 PFU is not statistically significant (P= 0.6452), there is a significant difference 122 between the survival of WA-1 challenged mice compared to Beta at the 10 3 PFU dose, where 123 WA-1 elicits higher survival (P= 0.0446). Despite the observations of enhanced virulence of 124 Delta in humans, 10 3 PFU challenge of K18-hACE2-mice mirrored WA-1 survival more so than 125 Alpha or Beta (Fig. 1A) . As expected, increasing the challenge dose to 10 4 PFU decreased 126 survival of K18-hACE2-mice for all strains (Fig. 1B) . At the 10 4 PFU challenge dose, Delta 127 resulted in 0% survival (Delta vs WA-1 P= 0.0002) (Fig. 1A-B) . The 10 4 PFU challenge dose also shortened the time to morbidity for Beta as well as Alpha (WA-1 vs Alpha P=0.0008; WA-1 129 vs Beta P=0.0122). As we suspected from an ancestral strain, total morbidity of WA-1 infected 130 groups was not observed at the either dose. Using a disease scoring system established 131 previously (T.Y.Wong, K. S. Lee, et al., JVI accepted for publication) we observed higher 132 average disease scores for Alpha and Beta than Delta in K18-hACE2 mice intranasally 133 challenged with 10 3 PFU (Alpha vs Delta P=0.0355; Beta vs Delta P=0.0039) (Fig. 1C-D) .

Interestingly, Delta's observable disease phenotypes remained low by day 6 when Alpha-and 135 Beta-challenged mice started to develop greater observable disease phenotypes consistent 136 with morbidity (Alpha vs Delta P=0.0056). Delta's disease phenotypes were scored higher 137 following 10 4 PFU challenge, where they progressed in a pattern similar to Alpha. Delta-138 challenged mice received higher average disease scores than Beta by day 6 post challenge 139 (Fig. 1D) . These experiments suggested that Delta compared to WA-1, Alpha, and Beta We 140 reasoned that these differences warranted further investigation.

Mice challenged with of Alpha or Delta experience unique disease manifestation. To gain 142 additional insights into the differences in pathogenesis of Alpha and Delta in K18 mice, we 143 focused on a challenge dose of 10 3 PFU which allows for differential disease manifestation 144 between Alpha and Delta. Rectal temperature and weight loss were monitored in mice 145 challenged with 10 3 PFU of Alpha or Delta. In agreement with their disease scores, Alpha 146 challenged mice had significant loss of body temperature (hypothermia) and weight loss 147 between days 5 and 6 post challenge ( Fig. 1E-F) . However, Delta-challenged mice maintained 148 body temperature and did not experience weight loss ( Fig. 1G-H) . At day 6 post challenge,

Alpha challenged mice had reached morbidity based on disease scoring and required 150 euthanasia as a humane endpoint. However, at day 6 Delta challenged mice remained below 151 euthanasia criteria. Collectively, these data demonstrate that Alpha and Delta cause distinct 152 disease profiles in K18-hACE2-mice.

154 lungs but lower amounts of viral RNA in the brain. It has been previously reported that 155 SARS-CoV-2 viral burden is highest two days after challenge (43) and based on our data we 156 recognize that Alpha variant will cause morbidity at day 6 post-challenge; however, Delta variant 157 challenge will not cause the same disease, or survival. Therefore, we aimed to evaluate viral 158 RNA burden at day 2 and 6 post challenge for Alpha or Delta challenge mice. At euthanasia on 159 day 2 and 6 the lung, brain, and nasal wash fluid were collected from challenged mice to 160 quantify viral RNA burden via nucleocapsid qRT-PCR. We observed that viral RNA burden was 161 remarkably similar between Alpha and Delta in the lung at both time points ( Fig. 2A ). In the 162 nasal wash, viral load was also detectable at similar levels for both Alpha and Delta at day 2. In 163 contrast to the lung, the viral RNA burden decreased to undetectable levels at day 6 for both 164 VOC (Fig. 2B) . Surprisingly, challenge with Delta did not lead to detectable levels of viral RNA in 165 the brain at either day 2 or day 6. In contrast, mice infected with Alpha exhibited low RNA levels 166 at day 2 and a 2-fold increase at day 6, suggesting viral replication in the brain over time (Fig.   167 2C). These observations suggest that Delta replicates efficiently in the airway in a manner 168 similar to Alpha but Delta appears to lack the brain localization previously observed in K18- 

Although not significant, a trend of lowered hACE2 expression occurred in Alpha challenged 213 mice, whereas Delta challenged mice appeared to experience only slightly reduced hACE2 214 expression (Fig. 5D ). These observations together with qRT-PCR nucleocapsid data described 215 above, suggest that with equal viral burden (same challenge dose and equal viral RNA burden), 216 the differences in LD100 of Alpha and Delta as well as the disease phenotypes are likely related 217 to differences in host response to VOC and not overall viral load.

Delta challenge causes a higher magnitude of host gene expression change compared to 219 Alpha. To compare the host responses of Delta-and Alpha-challenged mice, we mapped lung 220 RNA sequencing reads to the mouse genome. We observed that Alpha or Delta challenge in 221 K18-hACE2 mice result in distinct transcriptional changes. Two days after challenge with Alpha, 222 2,413 statistically significant genes (FDR P ≤ 0.04) were differentially expressed compared to 223 uninfected mice, a difference which increases more than two-fold to 5,664 genes at day 6. In 224 Delta groups, differential expression encompasses 3,048 and 4,489 genes respectively. Venn 

Due to the fact that GO term analysis identified T cell response genes to be enriched in Delta 246 challenged mice, we performed T cell receptor (TCR) clonotype analysis using RNAseq reads.

Within the uninfected mice, we detected ~50 total clonotypes. In Alpha-challenged mice, the 248 number of clones were decreased relative to uninfected at both day 2 and 6. By contrast, Delta-249 challenged mice had decreased clones at day 2, but we observed a 6-fold increase in TCR 250 clones at day 6 ( Fig. 7C ). In counts of unique TCR clonotypes, the same trends were observed: 251 at day 6, Delta challenge had the most total unique TCR clones compared to non-challenged 252 mice, day 6 post-Alpha challenged mice, and day 2 post Delta challenged mice (Fig. 7D ).

These data suggest that Delta may induce more robust T cell response.

Delta challenge causes increases interferon dependent gene expression. Gene expression 255 analysis focused by GO terms revealed Delta challenge induced expression of interferon 256 response genes (Fig. 7) . Interferon is an import regulator of the antiviral response in humans.

It's variable expression in response to specific variants exemplifies the differences in the host 258 response. TGTP1 and IFI211, two interferon related genes, are the highest-expressed genes in 259 Delta at day 6 at a fold change of 52,725 or 11,733 higher than in uninfected mice. In Alpha at 260 day 6 these genes are 3,367 and 591-fold higher than uninfected. Due to the important role of 

To test that hypothesis, we directly measured type I and II interferons in lung supernatants and 

In this study, we modeled the pathogenesis of SARS-CoV-2 variants of concern in the K18- 

Although viral gene reads in our analysis show no significant differences between Alpha and 311 Delta sgRNAs, it is possible that our selected timepoints were too late to detect the differences 312 previously reported at 10 and 24 hours post challenge, or that our challenge dose was too low.

Still, our abundant transcriptomic data suggest an extensive list of gene pathways that were 314 enriched during Delta but not Alpha infection.

We observed that 10 3 PFU challenge with Delta variant does not cause the dramatic weight loss 316 and hypothermia reported in models of Alpha and Beta challenge (17). One well known caveat 317 of the K18-hACE2-mouse model is the fact that WA-1, Alpha and Beta strains enter the brain 318 (43, 45, 46, (56) (57) (58) (59) (60) (61) (62) . However, it appears that Delta variant remains more localized in the lungs of 319 challenged mice (Fig. 3) (63) . It's generally accepted that the K18-hACE2-mice reach morbidity 320 due to brain infection, supported by manifestations of disease including hypothermia, and 321 inflammatory profiles. It is possible that the absence of brain infection due to Delta allows for an 322 increased survival time, leaving more time for the development of severe infection and 323 pneumonia in the lung, which could make Delta a better strain for modeling the respiratory 324 phenotypes of COVID-19 disease in K18-hACE2 mice.

We appreciate that the K18-hACE2-mouse model has caveats to consider. The transgenic 326 model expressing human ACE2 in addition to mouse ACE2 addresses SARS-CoV-2's higher 327 affinity for binding human ACE2, which reduces species tropism and allows virus to cause lethal 328 disease in the mice. As is common in transgenic protein expression, hACE2 under the epithelial 

Additional tissues were treated using TRIzol reagent or fixed before additional work in BSL2 

Mice were euthanized either when assigned a health score of 5 or above or at the end of the 405 experiment with an IP injection of Euthasol (390mg/kg) (Pentobarbital) followed by secondary 

1000μL of TRI Reagent was added to 500μL of brain homogenate for RNA purification. 419 420 qPCR SARS-CoV-2 viral copy number analysis of lung, brain, and nasal wash.

RNA purification of the lung, brain and nasal wash was performed using the Direct-zol RNA 422 miniprep kit (Zymo Research R2053) following the manufacturer protocol. SARS-CoV-2 copy 423 numbers were assessed through qPCR using the Applied Biosystems TaqMan RNA to CT One

Step 

Areas involved by inflammation were further evaluated by electron microscopic examination.

The areas of interest were punched from the paraffin embedded tissue block and processed for 

in no viral RNA burden in the brain (C). Dashed lines indicate limit of detection via qPCR.

NC=no challenge. 

Alpha or Delta challenged lung supernatants were used to determine local cytokine production 557 in response to challenge. Concentrations (pg/mL) were graphed using Morpheus to reveal 558 relative levels of cytokines compared to non-challenged lungs. 

Emergence of SARS-CoV-2 B.1.1.7 Lineage -United States

Detection of a SARS-CoV-2 variant of concern in South Africa

New Brazilian variant 596 of the SARS-CoV-2 (P1/Gamma) of COVID-19 in Alagoas state

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: 600 preliminary findings -SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology -601

Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant 606 circulation in São Paulo

Impact of 609 original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two 610 doses of COVID-19 mRNA vaccines

Lancet Reg Heal -Eur

COVID-19 vaccine 613 coverage in health-care workers in England and effectiveness of BNT162b2 mRNA 614 vaccine against infection (SIREN): a prospective, multicentre, cohort study

CoV2373 Covid-19 Vaccine against the B.1.351 Variant

ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Safety 623 and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sars-cov-2 variant of 626 concern 202012/01 has about twofold replicative advantage and acquires concerning 627 mutations

Acute Respiratory System Coronavirus 2 (SARS-CoV-2) Alpha Variant (B.1.1.7) in

The Disease Severity and Clinical Outcomes of the SARS-634

CoV-2 Variants of Concern. Front Public Heal

Mortality and critical 636 care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an 637 observational cohort study

Estimated 639 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased 643 risk of hospitalisation and intensive care admission associated with reported cases of 644

SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway

(alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-648 hACE2 transgenic mice distinct from early strains

The 650 alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and 651 requires lower inoculation doses to cause disease in K18-hACE2 mice

Progress of the COVID-19 654 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

SARS-CoV-2 variants of 660 concern are emerging in India

Effectiveness of COVID-19 vaccines against variants of concern

Canadian Immunization Research Network (CIRN) Provincial Collaborative Network 665 (PCN) Investigators. medRxiv

Delta 668 variants of SARS-CoV-2 cause significantly increased

BNT162b2 mRNA 671

Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that 679 affect recognition by polyclonal human plasma antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

The N501Y spike substitution 686 enhances SARS-CoV-2 transmission

Spike mutation 689 D614G alters SARS-CoV-2 fitness

Delta variant 691 (B.1.617.2) sublineages do not show increased neutralization resistance

Cellular and Molecular Immunology

Evolutionary 695 analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses

Enhanced fusogenicity and 699 pathogenicity of SARS-CoV-2 Delta P681R mutation

The neutralization 702 potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained 703 against viral variants

Multivalent designed proteins 705 protect against SARS-CoV-2 variants of concern

SARS-CoV-2 708 variants of concern infect the respiratory tract and induce inflammatory response in wild-709 type laboratory mice

Emerging SARS-CoV-2 712 variants expand species tropism to murines. EBioMedicine

SARS-CoV-2 714 variants of concern Alpha, Beta, Gamma and Delta have extended ACE2 receptor host-715 ranges. bioRxiv

Common laboratory 718 mice are susceptible to infection with the SARS-CoV-2 beta variant. Viruses

1 variants extend SARS-CoV-2 host range to mice

Evaluation of K18-725 hACE2 Mice as a Model of SARS-CoV-2 Infection

Animal models for COVID-19

K18-732 hACE2 mice develop respiratory disease resembling severe COVID-19

SARS-CoV-2 infection 735 of human ACE2-transgenic mice causes severe lung inflammation and impaired function

SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice

K18-741 hACE2 mice develop respiratory disease resembling severe COVID-19

Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-1 19 in Response to Infectious Dose of SARS-CoV-2 Virus 2 3

Interferon-alpha or -beta 751 facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2

Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and 755

The Innate Immune System: Fighting on the Front Lines or 758

Fanning the Flames of COVID-19?

Mouse model of SARS-CoV-2 761 reveals inflammatory role of type i interferon signaling

The dual nature of type I and type II interferons. Front Immunol

The ORF8 protein of SARS-CoV-2 765 mediates immune evasion through down-regulating MHC-Ι

Subgenomic RNA Expression in SARS-CoV-2 B.1.1.7 Infections Genomics UK

UK) consortium 11十 , Thushan I. de Silva 4,5 * Full list of consortium names and 770 affiliations located in the supplementary material *Corresponding Author Affiliations 1

Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

Lethal 777 Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome 778

Fatal 780 neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 781 expression

Controlled 784 administration of aerosolized SARS-CoV-2 to K18-hACE2 transgenic mice uncouples 785 respiratory infection and anosmia from fatal neuroinvasion 5

Neuroinvasion 788 and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice

Quantifying the relationship between sars-cov-2 viral load and infectiousness

Virological and 794 serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections a multi-795 center cohort study

Viral dynamics of 798 acute SARS-CoV-2 infection and applications to diagnostic and public health strategies

How the Delta variant achieves its ultrafast spread

Pathogenesis and 802 transmission of SARS-CoV-2 in golden hamsters

Syrian 804 hamsters as a small animal model for SARS-CoV-2 infection and countermeasure 805 development

Sars-cov-2 delta 808 variant pathogenesis and host response in syrian hamsters

An interactive tool for comparing lists with Venn's diagrams

WebGestalt 2019: gene set analysis toolkit 812 with revamped UIs and APIs